Health economic evaluation of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma: a systematic review

Table 4 Major results of health economic assessment of SBRT in the treatment of HCC

Included research	Intervention technique	Control technique	Incremental cost	Incremental output	ICER	Payment threshold	Basic conclusion
Hayeon Kim [17]	SBRT^c	RFA^d	8202	0.050	164,660	100,000^a	Not cost-effective
Leung [18]	Sorafenib	SBRT	969,041	0.260	3788,238	2213,145^b	Not cost-effective
Pollom [19]	SBRT–SBRT	RFA-SBRT	4269	0.008	558,679	100,000^a	Not cost-effective
	SBRT–RFA	RFA–SBRT	4,394	0.002	2197,000	100,000^a	Not cost-effective
	RFA–RFA	RFA–SBRT	283	− 0.012	–	100,000^a	Dominated
Leung [20]	Proton beam therapy	SBRT	557,907	2.610	213,354	2157,024^b	Cost-effective
Parikh [21]	SBRT	RFA	− 1967	− 0.035	56,301	100,000^a	Not cost-effective

^a The cost unit of incremental cost, ICER, and threshold value were in US dollars; ^b The cost unit of incremental cost, ICER, and threshold value were in New Taiwan dollars; ^c stereotactic body radiotherapy; ^d radiofrequency ablation; % ICER per life-year gained, not quality life-year gained

ISSN: 1478-7547